

## Diagnosis and management of SMA in older adolescents and adults

### Chair

Emma Ciafaloni, MD, FAAN, University of Rochester Medical Center, Rochester, NY, USA

### Faculty

John W. Day, MD, PhD, Stanford University School of Medicine, Stanford, CA, USA

Crystal Proud, MD, Children's Hospital of The King's Daughters, Norfolk, VA, USA

**Release date: October 1, 2021**

**Expiration date: October 1, 2022**

**Estimated time to completion: 1.5 hour**

**Available CME Credits: up to 1.5 AMA PRA Category 1 Credit(s)<sup>™</sup>**

### Activity description

In this educational activity, the leading experts Dr Emma Ciafaloni, Dr John Day, and Dr Crystal Proud will discuss specific considerations for the diagnosis and management of spinal muscular atrophy (SMA) in older adolescents and adults. They will address challenges in the timely diagnosis of SMA in this patient group, and highlight relevant steps in the diagnostic work-up. The experts will also examine clinical evidence on current treatment options and provide you with insights on how they implement optimal and personalized care for adolescents and adults with SMA at their clinics.

Furthermore, you will have a chance to explore two interactive patient cases that give practical insights on the diagnostic process and individual management of an adolescent and an adult patient with SMA. A supporting clinical practice guide will help you will help you recognize and diagnose SMA in adults.

### Target audience

This activity is intended for adult general neurologists, neuromuscular disease specialists, pediatric neurologists, general practitioners, and other healthcare professionals (HCPs) involved in the diagnosis and management of SMA.

### Educational objectives

After completing this activity, the participant should be better able to:

- **Recognize** signs and symptoms of SMA in older adolescents and adults and follow the optimal process for timely and accurate diagnosis
- **Evaluate** clinical evidence on current disease-modifying treatments for older adolescents and adult patients with SMA
- **Develop** individualized care plans for disease-modifying treatment and multidisciplinary management of adolescent and adult patients with SMA

- **Discuss** considerations for the transition of patients with SMA from pediatric to adult care providers and referral processes

### **Joint accreditation statement**

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Ology Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

### **Physician continuing medical education**

The Postgraduate Institute for Medicine designates this enduring material for a maximum of up to 1.5 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Method of participation and request for credit**

There are no fees for participating in, and receiving CME/CE credit for, this activity.

In order to claim credit, participants must complete the following procedures during the period October 1, 2021, through October 1, 2022:

1. Read the educational objectives, accreditation information, and faculty disclosures
2. View the webcast, interactive patient cases and practice guide
3. Take the post-activity test and complete the evaluation
4. Indicate the number of credits earned and download the certificate of CME credit

### **Disclosure of conflicts of interest**

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty	Relationship identified with:
Emma Ciafaloni, MD, FAAN	Consultant for: Alexion, Dyne, Janssen, Sarepta Contracted researcher for: HR Healthcarel, Novartis, Sarepta Royalties: Oxford Press
John W. Day, MD, PhD	Advisor for: Cure CMD, Cure SMA, Foundation Building Strength for Nemaline Myopathy, Muscular Dystrophy Association, Parent Project Muscular Dystrophy, SMA Foundation Advisory board for: AMO Pharma, Avidity Biosciences, Biogen, Cytokinetics, Novartis, Novartis Gene Therapies, Roche/Genentech Pharmaceuticals, Sarepta Therapeutics, Scholar Rock Consultant for: Affinia Therapeutics, Audentes Therapeutics, Ionis Pharmaceuticals, Pfizer Grant recipient for: Audentes, Biogen, Cytokinetics, Ionis Pharmaceuticals, Novartis Gene Therapies, Pfizer, Roche Pharmaceuticals, Sanofi-Genzyme, Sarepta Therapeutics, Scholar Rock
Crystal Proud, MD	Consultant for: AveXis/Novartis Gene Therapies, Biogen, Genentech/Roche, Sarepta, Scholar Rock Contracted researcher for: AMO Pharma, Astellas, AveXis/Novartis Gene Therapies, Biogen, CSL Behring, Fibrogen, Pfizer, PTC Therapeutics, Sarepta, Scholar Rock Speakers bureau: AveXis/Novartis Gene Therapies, Biogen

### Planners and managers

The PIM planners and managers have nothing to disclose. The Ology Medical Education planners and managers have nothing to disclose.

### Provider information

Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education.



**Financial support**

This activity is supported by an independent educational grant from Biogen MA, Inc.

**Disclosure of unlabeled use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

**Contact information for questions about the activity**

[info@ologyeducation.org](mailto:info@ologyeducation.org), [www.ologyeducation.org](http://www.ologyeducation.org)  
[inquiries@pimed.com](mailto:inquiries@pimed.com), [www.pimed.com](http://www.pimed.com)

**System requirements**

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

**Policy on Privacy and Confidentiality**

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

**Media**

Internet